Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer

被引:144
作者
Di Maio, Massimo
Chiodini, Paolo
Georgoulias, Vassilis
Hatzidaki, Dora
Takeda, Koji
Wachters, Floris M.
Gebbia, Vittorio
Smit, Egbert F.
Morabito, Alessandro
Gallo, Ciro
Perrone, Francesco
Gridelli, Cesare [1 ]
机构
[1] SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy
关键词
PATIENT DATA METAANALYSIS; PHASE-III TRIAL; DOCETAXEL; IRINOTECAN; MULTICENTER; GEMCITABINE; CISPLATIN; TIME;
D O I
10.1200/JCO.2008.17.5844
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Doublet chemotherapy is more effective than single-agent as first-line treatment of advanced non-small-cell lung cancer (NSCLC). As second-line treatment, several randomized trials have been performed comparing single-agent with doublet chemotherapy, but each trial had an insufficient power to detect potentially relevant differences in survival. Methods We performed meta-analysis of individual patient data from randomized trials, both published and unpublished, comparing single-agent with doublet chemotherapy as second-line treatment of advanced NSCLC. Primary end point was overall survival (OS). All statistical analyses were stratified by trial. Results Eight eligible trials were identified. Data of two trials were not available, and data of six trials (847 patients) were collected. Median age was 61 years. Performance status was 0 or 1 in 90%; 80% of patients had received previous platin-based chemotherapy. OS was not significantly different between arms (P = .32). Median OS was 37.3 and 34.7 weeks in the doublet and single-agent arms, respectively. Hazard ratio (HR) was 0.92 (95% CI, 0.79 to 1.08). Response rate was 15.1% with doublet and 7.3% with single-agent (P = .0004). Median progression-free survival was 14 weeks for doublet and 11.7 weeks for single agent (P = .0009; HR, 0.79; 95% CI, 0.68 to 0.91). There was no significant heterogeneity among trials for the three efficacy outcomes. Patients treated with doublet chemotherapy had significantly more grade 3 to 4 hematologic (41% v 25%; P = .0001) and grade 3 to 4 nonhematologic toxicity (28% v 22%; P = .034). Conclusion Doublet chemotherapy as second-line treatment of advanced NSCLC significantly increases response rate and progression-free survival, but is more toxic and does not improve overall survival compared to single-agent. J Clin Oncol 27: 1836-1843. (C) 2009 by American Society of Clinical Oncology
引用
收藏
页码:1836 / 1843
页数:8
相关论文
共 21 条
[1]  
ALBERTI W, 1995, BRIT MED J, V311, P899
[2]   Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer - A meta-analysis [J].
Delbaldo, C ;
Michiels, S ;
Syz, N ;
Soria, JC ;
Le Chevalier, T ;
Pignon, JP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (04) :470-484
[3]   Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non small-cell lung cancer [J].
Di Maio, Massimo ;
Perrone, Francesco ;
Chiodini, Paolo ;
Gallo, Ciro ;
Camps, Carlos ;
Schuette, Wolfgang ;
Quoix, Elisabeth ;
Tsai, Chun-Ming ;
Gridelli, Cesare .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (11) :1377-1382
[4]  
Ettinger David S, 2006, J Natl Compr Canc Netw, V4, P548
[5]   Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].
Fossella, FV ;
DeVore, R ;
Kerr, RN ;
Crawford, J ;
Natale, RR ;
Dunphy, F ;
Kalman, L ;
Miller, V ;
Lee, JS ;
Moore, M ;
Gandara, D ;
Karp, D ;
Vokes, E ;
Kris, M ;
Kim, Y ;
Gamza, F ;
Hammershaimb, L .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362
[6]   Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients The DISTAL-2 randomized trial [J].
Gebbia, Vittorio ;
Gridelli, Cesare ;
Verusio, Claudio ;
Frontini, Luciano ;
Aitini, Enrico ;
Daniele, Bruno ;
Gamucci, Teresa ;
Mancuso, Gianfranco ;
Di Maio, Massimo ;
Gallo, Ciro ;
Perrone, Francesco ;
Morabito, Alessandro .
LUNG CANCER, 2009, 63 (02) :251-258
[7]   Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine:: a multicenter randomised phase II study [J].
Georgoulias, V ;
Agelidou, A ;
Syrigos, K ;
Rapti, A ;
Agelidou, M ;
Nikolakopoulos, J ;
Polyzos, A ;
Athanasiadis, A ;
Tselepatiotis, E ;
Androulakis, N ;
Kalbakis, K ;
Samonis, G ;
Mavroudis, D .
BRITISH JOURNAL OF CANCER, 2005, 93 (07) :763-769
[8]   Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study [J].
Georgoulias, V ;
Kouroussis, C ;
Agelidou, A ;
Boukovinas, I ;
Palamidas, P ;
Stavrinidis, E ;
Polyzos, A ;
Syrigos, K ;
Veslemes, M ;
Toubis, M ;
Ardavanis, A ;
Tselepatiotis, E ;
Vlachonikolis, I .
BRITISH JOURNAL OF CANCER, 2004, 91 (03) :482-488
[9]   Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].
Hanna, N ;
Shepherd, FA ;
Fossella, FV ;
Pereira, JR ;
De Marinis, F ;
von Pawel, J ;
Gatzemeier, U ;
Tsao, TCY ;
Pless, M ;
Muller, T ;
Lim, HL ;
Desch, C ;
Szondy, K ;
Gervais, R ;
Shaharyar ;
Manegold, C ;
Paul, S ;
Paoletti, P ;
Einhorn, L ;
Bunn, PA .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597
[10]   Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis [J].
Johnson, Kent R. ;
Ringland, Clare ;
Stokes, Barrie J. ;
Anthony, Danielle M. ;
Freemantle, Nick ;
Irs, Alar ;
Hill, Suzanne R. ;
Ward, Robyn L. .
LANCET ONCOLOGY, 2006, 7 (09) :741-746